Invesco Pharmaceuticals ETF PJP
Set alert
As of Oct 30, 3:59 PM ET
- YTD
- +24.87%
- 1 year
- +36.58%
- Open
- 130.83
- Prev close
- 128.88
- Mkt cap
- 373.96M
- Vol
- 52.09K
- Avg vol
- 33.65K
- EPS
- 5.59
- P/E
- 23.35
- Div yield
- 0.00%
More statistics
- Low
- 130.30
- High
- 131.88
- Forward P/E
- 0.00
- Beta
- 0.00
- Short ratio
- 0.00
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 86.39
- 200-d avg
- 83.44
News
1 week ago fool.com
Invesco Pharmaceuticals ETF vs. iShares Biotechnology ETF: Which Is the Better Buy?
Here's how pharmaceutical stocks compare to biotech in terms of risk, rewards, and costs.
2 weeks ago businesswire.com
Papa Johns (PJP Investments Group) Puts People at the Centre of Growth with Blink Partnership
DUBAI, United Arab Emirates--(BUSINESS WIRE)--Papa Johns (PJP Investments Group), has partnered with Blink to bring a mobile-first digital experience to its 1,300-strong workforce.
2 weeks ago fool.com
Which Pharmaceuticals ETF Is the Better Buy: iShares’ IHE or Invesco’s PJP?
Pharmaceutical stocks have been one of the best places to invest over the past year. Choosing between these two funds is really a question about how you want to own what comes next.
3 weeks ago fool.com
Better Invesco Healthcare ETF: PJP Targeting Pharmaceuticals vs. RSPH's Broader Sector Lens
The Invesco S&P 500 Equal Weight Health Care ETF offers a lower expense ratio and broader diversification than the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF has generated higher…
4 weeks ago fool.com
Better Pharmaceuticals ETF: VanEck's PPH vs. Invesco PJP
The VanEck Pharmaceutical ETF offers a lower expense ratio of 0.36% compared to 0.58% for the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF has delivered a higher 1-year total return…
1 month ago zacks.com
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
The Invesco Pharmaceuticals ETF (PJP) was launched on 06/23/2005, and is a smart beta exchange traded fund designed to offer broad exposure to the Health Care ETFs category of the market.
1 month ago fool.com
XLV vs. PJP: How Broad Healthcare Diversification Stacks Up to Pharma Stocks
The State Street Health Care Select Sector SPDR ETF (XLV) offers significantly lower ownership costs, with an expense ratio of 0.08% compared to 0.58% for the Invesco Pharmaceuticals ETF (PJP). PJP…
1 month ago fool.com
Invesco Pharmaceuticals vs iShares Healthcare: Which Healthcare ETF Brings Better Profits
Invesco's concentrated 30-stock pharma fund delivered 43.1% returns last year, but iShares' broader 100-holding portfolio costs less and offers wider sector exposure.
1 month ago benzinga.com
What's Going On With Amgen Stock Tuesday?
AMGN stock dips 9% after rival drug trial misses goal. Discover Amgen key support levels, technical outlook, and analyst price targets
1 month ago zacks.com
Should You Invest in the Invesco Pharmaceuticals ETF (PJP)?
Launched on June 23, 2005, the Invesco Pharmaceuticals ETF (PJP) is a passively managed exchange traded fund designed to provide a broad exposure to the Healthcare - Pharma segment of the equity…
2 months ago defenseworld.net
Bank of America Corp DE Has $7.73 Million Stock Holdings in Invesco Pharmaceuticals ETF $PJP
Bank of America Corp DE raised its stake in shares of Invesco Pharmaceuticals ETF (NYSEARCA:PJP) by 234.0% during the first quarter, according to its most recent disclosure with the Securities and…
2 months ago fool.com
FHLC vs. PJP: Which Healthcare ETF Is the Better Buy for Investors?
Fidelity MSCI Health Care Index ETF (FHLC) offers a significantly lower expense ratio and a higher dividend yield than the Invesco Pharmaceuticals ETF (PJP). PJP provides a concentrated portfolio of…
2 months ago fool.com
XPH vs PJP: Which Pharma ETF Offers Better Value
The State Street SPDR S&P Pharmaceuticals ETF offers a significantly lower expense ratio of 0.35% compared to the Invesco Pharmaceuticals ETF. The Invesco Pharmaceuticals ETF provides a more…
2 months ago barrons.com
These New Drugs Could Fuel Fresh Highs for Biotech and Pharma Stocks
Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.
3 months ago invezz.com
Nikkei 225, Kospi jolt Asian markets as AI rout and Fed fears collide
Asian stocks were mixed on Thursday as investors assessed the fallout from the AI sell-off, the Federal Reserve's rate outlook and renewed tensions in the Middle East. The MSCI Asia-Pacific gauge…
3 months ago zacks.com
Is Invesco Pharmaceuticals ETF (PJP) a Strong ETF Right Now?
Launched on 06/23/2005, the Invesco Pharmaceuticals ETF (PJP) is a smart beta exchange traded fund offering broad exposure to the Health Care ETFs category of the market.
3 months ago benzinga.com
Two Years to Build or Pay 200% — Which US Pharma Stocks Win?
Trump sets a 2-year ultimatum for generic drugmakers to reshore U.S. production or face tariffs up to 200%.
3 months ago fool.com
As Healthcare Rallies Is the Vanguard Health Care ETF of the Invesco Pharmaceuticals ETF the Better Fund for 2026?
Vanguard Health Care ETF offers a lower expense ratio and higher dividend yield than Invesco Pharmaceuticals ETF Invesco Pharmaceuticals ETF has concentrated its portfolio in 29 pharmaceutical stocks…
3 months ago invezz.com
Kospi jumps 6% as Asia's battered semiconductor trade rebounds
Asian stocks rallied on Wednesday as investors returned to semiconductor shares after a bruising sell-off, taking their cue from a Wall Street rebound even as Brent crude pushed further above $91 a…
3 months ago fool.com
Will the Invesco Pharma ETF or iShares Global Healthcare Fund Be the Better Health Care Fund in 2026?
IXJ offers broader diversification with 110 holdings and a lower 0.40% expense ratio, while PJP's concentrated U.S. pharma strategy delivered a 44.90% one-year return.
3 months ago fool.com
PJP vs. IYH: Which Healthcare ETF Is the Better Buy?
The iShares U.S. Healthcare ETF (IYH) offers a broader portfolio with a lower expense ratio than the Invesco Pharmaceuticals ETF (PJP). PJP has delivered significantly higher total returns over the…
3 months ago fool.com
Invesco Pharmaceuticals ETF vs State Street Biotech ETF: Which Fund Is the Better Buy in 2026?
Invesco Pharmaceuticals ETF offers a higher dividend yield and lower five-year beta than State Street SPDR S&P Biotech ETF State Street SPDR S&P Biotech ETF holds 155 securities compared to 30 in…
6 months ago benzinga.com
Amgen Posts 77% Response In Thyroid Eye Disease Study
Amgen shares fall despite Phase 3 TEPEZZA OBI data showing 77% response rate and proptosis reduction in thyroid eye disease patients.
8 months ago benzinga.com
Pfizer's Cancer Drug Combo Shows Strong Results In Key Colorecatal Cancer Trial
Pfizer's Braftovi combo improves survival in advanced colorectal cancer trial.
9 months ago benzinga.com
Trump Unveils 'Great Healthcare Plan,' Takes Aim At PBM 'Kickbacks'
Trump's "Great Healthcare Plan" targets PBM kickbacks to cut costs. Experts confirm these fees act as an industry "vig" driving up prices.
11 months ago benzinga.com
Eli Lilly CEO Slams PBM 'Rent Taking', Says They Drove Insulin List Prices To $275: 'We Can Disintermediate Them Easily'
Eli Lilly CEO Dave Ricks slams PBM "rent taking" for driving $275 insulin price bubble and explains why he's ready to "disintermediate them."
1 year ago benzinga.com
Trump's 100% Drug Tariff Will Hit Americans, Economist Says Buyers 'Eat The Cost,' Not Foreign Firms
President Donald Trump's proposed 100% tariffs on foreign pharmaceuticals will ultimately be paid by American patients and insurers, not foreign drug companies, according to economist Justin Wolfers.
1 year ago benzinga.com
Mark Cuban Exposes How Wholesalers Force Pharmacies Into Near-Exclusive Deals, Detailing PBMs' 'Stranglehold' On Drug Pricing
Mark Cuban explains how PBMs & wholesalers force pharmacies into exclusive deals, creating a 'stranglehold' on prescription drug prices.
1 year ago benzinga.com
Mark Cuban Says Cutting PBM Fees Won't Reduce Pharmaceutical R&D Funding: 'Manufacturers Can Sell To Us For More'
Mark Cuban challenges the idea that high drug prices are necessary for R&D, PBMs take away from profits, leaving less for innovation.
1 year ago benzinga.com
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk.
1 year ago benzinga.com
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest.
1 year ago benzinga.com
Mark Cuban Corrects Elizabeth Warren As She Slams JNJ, PFE For Higher Prices And Zero Taxes On Big Pharma: 'PBMs Corrupt Healthcare'
A debate over the healthcare system erupted on X, pitting Mark Cuban against Elizabeth Warren over the root causes of soaring drug prices.
1 year ago benzinga.com
Trump's Drug Price Order Hits PBMs Hardest: CVS, Cigna, UNH In Focus As Experts Highlight 'Racket,' Pricing Distortion
Trump signed an executive order to lower drug prices, which could hit pharmacy benefit managers (PBMs) hard. PBMs have come under scrutiny for opaque pricing practices. Mark Cuban calls PBMs a racket.
1 year ago benzinga.com
Trump Says Prescription Drug Prices Set To Drop By 30% To 80% 'Almost Immediately' Thanks To 'Most Favored Nation' Plan, Mark Cuban Urges President To 'Force Transparency'
Trump vows to slash drug prices with new executive order, potentially dropping them by 30-80%.
1 year ago benzinga.com
Trump Administration Considers Lowering US Drug Prices To International Levels: Report
The Trump Administration is reportedly mulling over a policy to match U.S. drug prices with those in other developed nations.
1 year ago benzinga.com
Eli Lilly, AbbVie, Bristol Myers, Regeneron, And Other Pharma Companies Slide As Donald Trump Confirms Tariffs On Pharma Companies
Even as Donald Trump paused the reciprocal tariffs for 90 days, he later confirmed that pharmaceutical companies would face tariffs.
-
1 year ago benzinga.com
FDA Commissioner Califf Candid on Trump's Impact: 'We Just Don't Know What's Going to Happen'
FDA Chief Robert Califf reflects on potential changes as Trump's re-election looms, expressing disappointment and highlighting uncertainty within the agency.
-
2 years ago benzinga.com
FDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To Watch
The FDA may approve updated COVID-19 vaccines this week to combat recent strains as the country endures a significant summer outbreak.
-
2 years ago benzinga.com
COVID Activity Is Elevated Across 26 States In Summer Surge, Biden Remains In Isolation: 3 Vaccine Stocks To Watch
Over half of US states have high levels of Covid-19 in wastewater as President Biden isolates with virus. New vaccines expected by Sept.
-
9 years ago benzinga.com
Mr. Wonderful's Election Week Trades For A Trump Victory
Mr. Wonderful's Election Week Trades For A Trump Victory
-
10 years ago benzinga.com
Government Study: Cellphone Radiation Linked To Cancer
Government Study: Cellphone Radiation Linked To Cancer
-
14 years ago benzinga.com
Arena Approval Boosts Biotech ETFs (ARNA, IBB, XBI)
Arena Approval Boosts Biotech ETFs (ARNA, IBB, XBI)
-
14 years ago benzinga.com
The Definitive Biotech ETF Guide (IBB, XBI, FBT)
The Definitive Biotech ETF Guide (IBB, XBI, FBT)
-
14 years ago benzinga.com
S&P Bullish On Biotech ETFs (FBT, IBB, XBI)
S&P Bullish On Biotech ETFs (FBT, IBB, XBI)
-
14 years ago benzinga.com
Viva Vivus, But Not In ETFs (VVUS, IBB, PJP)
Viva Vivus, But Not In ETFs (VVUS, IBB, PJP)
-
15 years ago benzinga.com
Bristol-Myers and Quidel to Open Near 52-Week Highs
Bristol-Myers and Quidel to Open Near 52-Week Highs
-
15 years ago benzinga.com
Fifteen Health Care ETFs Trading Near 52-Week Highs
Fifteen Health Care ETFs Trading Near 52-Week Highs
-
15 years ago benzinga.com
Twelve Health Care ETFs Trading Near 52-Week Highs
Twelve Health Care ETFs Trading Near 52-Week Highs